Objective To investigate the clinical efficacy of Liuwei Anshen capsule combined with Escitalopram in the treatment of depression.Methods A totoal of 150 patients with depression who were treated in 904th Joint Logistics Support Force Hospital Chan-gzhou Medical Area from January 2022 to January 2024 were selected as the study objects.Patients were divided into group A(n=72)and group B(n=78)according to different treatment regiments.Group A was treated with escitalopram,group B was treated with Li-uwei Anshen capsule combined with Escitalopram.The clinical efficacy and incidence of adverse reactions were recorded and compared between the two groups.The score of short form 36 questionnaire(SF-36),beck scale for suicide ideation(BSS),neurotransmitter[nor-epinephrine(NE),5-hydroxy tryptamine(5-HT),dopamine dopamine(DA)],inflammatory factors[interleukin(IL)-6,IL-22,IL-1β]before and after treatment were compared between the two groups.And the expression level of toll-like receptor 4/NOD-like receptor 3(TLR4/NLRP3)pathway.Results The total effective rate of group B was 89.74%(70/78),which was higher than 59.72%(43/72)of group A,and the difference was statistically significant(P＜0.05).After treatment,SF-36 score increased and BSS score decreased in both groups,and SF-36 score in group B was higher than that in group A,and BSS score was lower than that in group A,with statisti-cal significance(P＜0.05).After treatment,IL-6,IL-21 and IL-1β in 2 groups were decreased,while NE,5-HT and DA were in-creased,and IL-6,IL-21 and IL-1β in group B were lower than those in group A,while NE,5-HT and DA were higher than those in group A,with statistical significance(P＜0.05).After treatment,TLR4 mRNA and NLRP3 mRNA were decreased in 2 groups,and group B was lower than group A,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in group A and group B was 2.78%(2/72)and 3.85%(3/78),respectively,with no statistical significance(P＞0.05).Conclusion Liuwei Anshen capsule combined with Escitalopram is effective in the treatment of depression,and can improve symptoms,levels of inflamma-tory factors and neurotransmitters.The down-regulation of pro-inflammatory factors such as IL-6,IL-21 and IL-1β may be related to the inhibition of TLR4/NLRP3 pathway expression.
维普
万方数据
